Profile of Epratuzumab and Its Potential in the Treatment of Systemic Lupus Erythematosus

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2014 Nov 28

PMID 25429203

Citations 6

Authors

Hanan Al Rayes

Zahi Touma

Affiliations

Soon will be listed here.

Abstract

Management of systemic lupus erythematosus (SLE) represents a fascinating, emerging field. Research has recently provided us with a better understanding of the immunologic alterations of SLE, leading to the creation of immunomodulatory agents designed to disrupt specific cell targets and pro-inflammatory pathways. Despite the improvement in the prognosis of SLE in the last 50 years with the use of immunosuppressive therapy such as cyclophosphamide and mycophenolate mofetil, cytotoxicity remains a major complication of these medications and the need for more specific targeted immunotherapy is increasing. Early recognition and treatment of SLE with targeted immunotherapy has the potential to improve quality of life and reduce the risk of disease flare-ups and complications. In this review, we will explore the role of B-cells in the pathogenesis of SLE highlighting current insights into SLE development and management. In addition, we will discuss epratuzumab's role in the treatment of SLE. Epratuzumab is a humanized anti-CD22 monoclonal antibody that targets CD22 on B-cell and its role in B-cell modulation, migration, function, and inhibition of B-cell receptor signaling. Epratuzumab is currently in a Phase III study evaluating its efficacy in the management of moderate to severe SLE. All published trials on epratuzumab have shown great promise with safe profiles.

Citing Articles

Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.

Panuciak K, Margas M, Makowska K, Lejman M Cells. 2022; 11(1).

PMID: 35011701 PMC: 8749975. DOI: 10.3390/cells11010139.

Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.

Li J, Wei M, Song Q, Guo X, Shao L, Liu Y Exp Ther Med. 2019; 18(2):1500-1506.

PMID: 31316634 PMC: 6601380. DOI: 10.3892/etm.2019.7630.

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.

Bangert E, Wakani L, Merchant M, Strand V, Touma Z Patient Relat Outcome Meas. 2019; 10:1-7.

PMID: 30666173 PMC: 6330963. DOI: 10.2147/PROM.S134326.

Recent advances in the management of systemic lupus erythematosus.

Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini M F1000Res. 2018; 7.

PMID: 30026918 PMC: 6039948. DOI: 10.12688/f1000research.13941.1.

Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.

Zhao Q, Chen X, Li J, Jiang J, Li M, Zhong W Clin Drug Investig. 2016; 36(11):889-902.

PMID: 27424629 DOI: 10.1007/s40261-016-0426-7.

References

Rovin B . Targeting B-cells in lupus nephritis: should cautious optimism remain?. Nephrol Dial Transplant. 2012; 28(1):7-9. DOI: 10.1093/ndt/gfs319. View

Dorner T, Jacobi A, Lipsky P . B cells in autoimmunity. Arthritis Res Ther. 2009; 11(5):247. PMC: 2787254. DOI: 10.1186/ar2780. View

Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9):2368-79. DOI: 10.1002/art.38037. View

Isenberg D, Rahman A, Allen E, Farewell V, Akil M, Bruce I . BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005; 44(7):902-6. DOI: 10.1093/rheumatology/keh624. View

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

Rahman A, Isenberg D . Systemic lupus erythematosus. N Engl J Med. 2008; 358(9):929-39. DOI: 10.1056/NEJMra071297. View

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

Touma Z, Urowitz M, Ibanez D, Gladman D . SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011; 20(1):67-70. DOI: 10.1177/0961203310385163. View

Bootsma H, Spronk P, Derksen R, de Boer G, Hermans J, Limburg P . Prevention of relapses in systemic lupus erythematosus. Lancet. 1995; 345(8965):1595-9. DOI: 10.1016/s0140-6736(95)90114-0. View

10.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P . Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999; 26(2):490-7. View

11.

Jacobi A, Goldenberg D, Hiepe F, Radbruch A, Burmester G, Dorner T . Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2007; 67(4):450-7. DOI: 10.1136/ard.2007.075762. View

12.

Williams M, Densmore J, Pawluczkowycz A, Beum P, Kennedy A, Lindorfer M . Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006; 177(10):7435-43. DOI: 10.4049/jimmunol.177.10.7435. View

13.

Touma Z, Gladman D, Ibanez D, Urowitz M . Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2010; 38(2):275-84. DOI: 10.3899/jrheum.100724. View

14.

Condon M, Ashby D, Pepper R, Cook H, Levy J, Griffith M . Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013; 72(8):1280-6. DOI: 10.1136/annrheumdis-2012-202844. View

15.

Furie R, Petri M, Wallace D, Ginzler E, Merrill J, Stohl W . Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009; 61(9):1143-51. PMC: 2748175. DOI: 10.1002/art.24698. View

16.

Tedder T, Tuscano J, Sato S, Kehrl J . CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997; 15:481-504. DOI: 10.1146/annurev.immunol.15.1.481. View

17.

Dorner T, Goldenberg D . Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2008; 3(5):953-9. PMC: 2376077. View

18.

Strand V, Petri M, Kalunian K, Gordon C, Wallace D, Hobbs K . Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2013; 53(3):502-11. PMC: 3930886. DOI: 10.1093/rheumatology/ket378. View

19.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

20.

Chan O, Shlomchik M . A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998; 160(1):51-9. View